

AD \_\_\_\_\_

Award Number: DAMD17-00-1-0518

TITLE: Expression and Purification of a Potential Antidote for  
Organophosphate Warfare Agents

PRINCIPAL INVESTIGATOR: Kenneth D. Lanclos, Ph.D.

CONTRACTING ORGANIZATION: Augusta Biomedical Research Corporation  
Augusta, GA 30901

REPORT DATE: July 2003

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;  
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**REPORT DOCUMENTATION PAGE**Form Approved  
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

**1. AGENCY USE ONLY**  
(Leave blank)**2. REPORT DATE**  
July 2003**3. REPORT TYPE AND DATES COVERED**  
Annual (Jul 1, 2002 - Jun 30, 2003)**4. TITLE AND SUBTITLE**

Expression and Purification of a Potential Antidote for Organophosphate Warfare Agents

**5. FUNDING NUMBERS**

DAMD17-00-1-0518

**6. AUTHOR(S)**

Kenneth D. Lanclos, Ph.D.

**7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)**Augusta Biomedical Research Corporation  
Augusta, GA 30901

E-Mail: Jkl42@comcast.net

**8. PERFORMING ORGANIZATION  
REPORT NUMBER****9. SPONSORING / MONITORING****AGENCY NAME(S) AND ADDRESS(ES)**U.S. Army Medical Research and Materiel Command  
Fort Detrick, Maryland 21702-5012**10. SPONSORING / MONITORING  
AGENCY REPORT NUMBER**

20030929 015

**11. SUPPLEMENTARY NOTES**

Original has color plates: All DTIC reproductions will be in black and white

**12a. DISTRIBUTION / AVAILABILITY STATEMENT**

Approved for Public Release; Distribution Unlimited

**12b. DISTRIBUTION CODE****13. ABSTRACT (Maximum 200 Words)**

Serine-dependent carboxylesterases (E.C.3.1.1.1) are found in a variety of tissues with high activity detected in the human liver. Carboxylesterases (CaE) hydrolyze aliphatic and aromatic esters, and aromatic amides; and play an important role in the detoxification of xenobiotic chemicals that contain organophosphate (OP) compounds. Thus, an injectable form of human hCaE should prove to be a valuable antidote for protecting soldiers from these chemical agents. The goals of this project are to over express a functional human liver hCaE from a recombinant cDNA in a human cell line, and isolate and purify the recombinant protein. To accomplish these goals, the cDNA encoding hCaE was altered in order to convert it to a secretory form. Expression of the site-mutated cDNA in cell culture resulted in the secretion of an active hCaE into the growth medium. Thus, the secreted hCaE enzyme will be concentrated and purified using hydrophobic interaction chromatography, Cibacron blue affinity chromatography, and isoelectric focusing chromatography. The long-term goal of the project is to isolate quantities sufficient for crystallization with organophosphate agents and to evaluate its use for protection by enzymatic detoxification of organophosphate nerve agents in an animal model.

**14. SUBJECT TERMS**

Carboxylesterase; cDNA cloning; cell culture; protein secretion, enzyme purification; Organophosphate detoxification

**15. NUMBER OF PAGES**

9

**16. PRICE CODE****17. SECURITY CLASSIFICATION  
OF REPORT**

Unclassified

**18. SECURITY CLASSIFICATION  
OF THIS PAGE**

Unclassified

**19. SECURITY CLASSIFICATION  
OF ABSTRACT**

Unclassified

**20. LIMITATION OF ABSTRACT**

Unlimited

## Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	5
Key Research Accomplishments .....	5-7
Conclusions.....	7
References.....	8-9

**Commander  
US. Army Medical Research and Materiel Command  
Attn: MCMR-RMI-S  
504 Scott Street  
Fort Detrick MD 21702-5012**

**Re: annual progress report: DAMD17-00-1-0518 - Expression and Purification of a Potential Antidote for Organophosphate Warfare Agents**

**Kenneth D. Lanclos, Ph.D., Principal Investigator**

### **Introduction:**

The serine-dependent carboxylesterases (E.C. 3.1.1.1) are found in many different species (1-8), and in a variety of tissues (9-14), with high activities detected in the liver. Generally, carboxylesterases exist as 60 kDa monomers, but a few associate to form homotrimers of approximately 180 kDa (1-4). cDNA clones have been obtained by screening lambda gt11 expression libraries. Their screenings have resulted in the expression of five isoenzymes of rat liver carboxylesterase (5-9) and at least two isoenzymes from the human liver (10-12). The cDNA sequences are, generally, 1.7 to 1.9 kb in size, and they encode mature proteins that range from 507 to 568 amino acids. The different isoenzymes of liver carboxylesterases are all N-linked glycoproteins of the high mannose type (5,6,12,13). Core glycosylation of the carboxylesterases occurs in the endoplasmic reticulum lumen (14,15), and, thus it is necessary to stabilize the active conformation of the protein (6,16). Whereas, most glycosylated proteins are secretory, the carboxylesterases are localized to the luminal side of the endoplasmic reticulum, especially in humans (4-6). Very small amounts of liver carboxylesterase, however, are present in the serum (17). Carboxylesterases can hydrolyze a variety of substrates in the serum, including aliphatic and aromatic esters, and aromatic amides (18). An important function of these enzymes may be the hydrolysis, and subsequent detoxification, of pesticides, insecticides and drugs (18), many of which contain organophosphate compounds that bind covalently to the active site of the enzymes (19,20). In this regard, the carboxylesterases generally function as a high affinity-low capacity detoxification mechanism, in which organophosphates react in an irreversible 1:1 stoichiometry (17). Thus, the detoxifying ability of carboxylesterase is limited by its low concentration in serum where it encounters organophosphate compounds. A treatment for organophosphate toxicity is the administration of oximes, which reactivate inhibited acetylcholinesterase and restore cholinergic neurotransmission (17). Species with high levels of serum carboxylesterase, such as rats and mice, achieve a higher level of oxime-induced reactivation of organophosphate-inhibited acetylcholinesterase than species with lower levels of carboxylesterase; this suggests that oximes also reactivate organophosphate-inhibited carboxylesterase (17). This recycling of organophosphate-

inhibited carboxylesterase provides additional protection by making the enzyme available for further binding to organophosphates, and thus, increased detoxification.

### **Body:**

The goals of this project are to over express a functional human liver hCaE from a recombinant cDNA in a human cell line, and isolate and purify the recombinant protein. To accomplish these goals, the cDNA encoding hCaE was altered in order to convert it to a secretory form. Expression of the site-mutated cDNA in cell culture resulted in the secretion of an active hCaE into the growth medium. Thus, the secreted hCaE enzyme will be concentrated and purified using hydrophobic interaction chromatography, Cibacron blue affinity chromatography, and preparative isoelectric focusing chromatography.

The long-term objective of the project is to isolate quantities sufficient to evaluate its use for protection by enzymatic detoxification of organophosphate nerve agents in an animal model. The short-term goals of this study are to maximize the expression of a functional recombinant secretory form of human liver carboxylesterase using a steady state human cell culture system, and to isolate and purify the recombinant enzyme from the culture media.

### **Key Research Accomplishments: (July 1, 2002 to July 26, 2003)**

Stable clones of 293T cells, stably transfected with the plasmid pRC/mhCaE were placed in liquid culture for expression of the secretory form of human liver carboxylesterase. Carboxylesterase activity was observed to increase as early as 24 hours and to reach a maximum at day four (21). Cultured cells were separated from the media by low speed centrifugation and the pooled media from several cultures was used for the isolation of purification enzymatically active enzyme.

Carboxylesterase was precipitated from the pooled media and precipitated using 70% saturated ammonium sulfate. The precipitate from the ammonium sulfate fraction was dissolved in 20 mM Hepes, pH 7.0 and applied to an octyl Sepharose column (21) for Hydrophobic Interaction Chromatography (HIC). Previous observations had shown that HIC chromatography using octyl Sepharose, coupled with octylglucoside in the elution buffer resulted in an enhanced partial purification of carboxylesterase. However, the major contaminant of the preparation, bovine serum albumin, as well as several minor contaminants, were not removed by this procedure.

Based on our previous observations (21) that carboxylesterase binds to many matrices used in standard protein purification procedures, we developed a liquid isoelectric focusing preparative system. The strategy was to remove the bulk of the BSA

(pI 4.9) from the carboxylesterase (pI 5.3) by precipitation of the BSA into the bottom of the column at around pH 4.0. A typical isoelectric focusing chromatogram (Figure 1) shows that BSA spills over into the pI 5.3 region and contaminates the carboxylesterase peak at pI 5.3. The fractions containing carboxylesterase activity and the small amount of contaminating BSA were then collected and used for a second run on the isoelectric focusing column. Following the second isoelectric focusing, the contaminating media proteins completely separate from the carboxylesterase fractions (figure 2). Furthermore, polyacrylamide gel electrophoresis zymograms of the carboxylesterase peak show only a single carboxylesterase band.

One of the major goals of this project was to be able to purify sufficient carboxylesterase to allow for crystallization studies on the enzyme. To date, we have provided 6mg of pure recombinant human liver carboxylesterase to DR. Steven Kirby, USAMRICD to begin a collaboration crystallization studies with OP compounds.




Figure 1: Preparative Electric Focusing Chromatogram




Figure 2: Preparative Electric Focusing Chromatogram

### Conclusion:

Clones containing the secretory form of human liver carboxylesterase were used to establish culture conditions where the enzyme is produced maximally in the 293T human cell line. This objective was accomplished by growing cells in a chemostat where the cells are maintained in a constant exponential phase of growth. In addition, conditions were defined which allow for an optimal time of removal of the culture media for isolation of carboxylesterase. Enzyme was isolated from the culture media, and the initial steps of enzyme purification using ammonium sulfate precipitation, HIC chromatography, and preparative liquid isoelectric focusing were accomplished. In the final steps of purification, the use of preparative liquid isoelectric focusing chromatography was found to be productive and resulted in a preparation that was free of bovine serum albumin and other minor contaminants as measure by polyacrylamide gel electrophoresis. Pure carboxylesterase has been supplied to the USAMRICD to begin crystallization studies with OP compounds.

## References:

1. Junge, W., Heymann, E., Krisch, K. and Hollandt, H. (1974) Human liver carboxylesterase. *Arch. Biochem. Biophys.* **165**, 749-763.
2. Miller, S. K., Main, A. R. and Rush, R. S. (1980) Purification and physical properties of oligomeric and monomeric carboxylesterases from rabbit liver. *J. Biol. Chem.* **255**, 7161-7167.
3. Mentlein, R., Ronai, A., Robbi, M., Heymann, E., and Deimling, O. (1987) Genetic identification of rat liver carboxylesterases located in different laboratories. *Biochim. Biophys. Acta* **913**, 27-38.
4. Ozols, J. (1989) Isolation, properties, and the complete amino acid sequence of a second form of a 60-kDa glycoprotein esterase. *J. Biol. Chem.* **264**, 12533-12545.
5. Long, R. M., Satoh, H., Martin, B., Kimura, S., Gonzales, F. J. and Pohl, L. R. (1988) Rat liver carboxylesterase: cDNA cloning, sequencing, and evidence for a multigene family. *Biochem. Biophys. Res. Commun.* **156**, 866-873.
6. Robbi, M., Beaufay, H. and Octave, J. N. (1990) Nucleotide sequence of cDNA coding for rat liver pI-6.1 esterase (ES-10), a carboxylesterase located in the lumen of the endoplasmic reticulum. *Biochem. J.* **269**, 451-458.
7. Robbi, M. and Beaufay, H. (1994) Cloning and sequencing of rat liver carboxylesterase ES-3 (Egasyn). *Biochem. Biophys. Res. Commun.* **203**, 1404-1411.
8. Yan, B., Yang, D., and Parkinson, A. (1995) Cloning and expression of hydrolase C, a member of the rat carboxylesterase family. *Arch. Biochem. Biophys.* **317**, 222-234.
9. Robbi, M., Van Schaftingen, E. and Beaufay, H. (1996) Cloning and Sequencing of rat liver carboxylesterase ES-4 (microsomal palmitoyl-CoA hydrolase). *Biochem. J.* **313**, 821-826.
10. Long, R. M., Calabrese, M. R., Martin, B. M. and Pohl, L. R. (1991) Cloning and sequencing of a human liver carboxylesterase isoenzyme. *Life Sci.* **48**, PL-43-PL-49.
11. Shibata, F., Takagi, Y., Kitajima, M., Kuroda T. and Omura, T. (1993) Molecular cloning and characterization of a human carboxylesterase gene. *Genomics* **17**, 76-82.
12. Kroetz, D. L., McBride, O. W., and Gonzales, F. J. (1993) Glycosylation-dependent



activity of baculovirus-expressed human liver carboxylesterases: cDNA cloning and characterization of two highly similar enzyme forms. *Biochemistry* **32**, 11606-11617.

13. Robbi, M. and Beaufay, H. (1988) Immunochemical characterization and biosynthesis of pI-6.4 esterase, a carboxylesterase of rat liver microsomal extracts. *Biochem. J.* **254**, 51-57.
14. Robbi, M. and Beaufay, H. (1986) Biosynthesis of rat liver pI-5.0 esterases in cell-free systems and in cultured hepatocytes. *Eur. J. Biochem.* **158**, 187-194.
15. Robbi, M. and Beaufay, H. (1987) Biosynthesis of rat liver pI-6.1 esterase, a carboxylesterase of the cisternal space of the endoplasmic reticulum. *Biochem. J.* **248**, 545-550.
16. Robbi, M. and Beaufay, H. (1992) Topogenesis of carboxylesterases: a rat liver isoenzyme ending in -HTEHT-COOH is a secreted protein. *Biochem. Biophys. Res. Commun.* **183**, 836-841.
17. Maxwell, D. M. (1992) Detoxication of organophosphorus compounds by carboxylesterase in "*Organophosphates: Chemistry, fate and effects*" (Chambers, J. E. and Levi, P. E., Eds.), pp.183-199, Academic Press, San Diego.
18. Leinweber, F. J. (1987) Possible physiological roles of carboxylic ester hydrolases. *Drug Metab. Rev.* **18**, 379-439.
19. Sterri, S. H., and Fonnum, F. (1987) Carboxylesterases in guinea pig plasma and liver. *Biochem. Pharmacol.* **36**, 3937-3942.
20. Sterri, S. H. (1989) The importance of carboxylesterase detoxification of nerve agents. *Proc. 3rd Int. Symp. Protection Against Chemical Warfare Agents, Sweden*, pp.235-240.
21. Miller, A.D., Scott, D.F., Chacko, T.L., Maxwell, D.M., Schlager, J.J., and Lanclos, K.D. (1999), Expression and Purification of a Recombinant Secretory Form of Human Liver Carboxylesterase. *Protein Expression and Purification* **17**, 16-25